Th22细胞及IL-22在肿瘤中的作用

doi:10.3760/cma.j.issn.1673-422X.2014.02.005

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (2): 93-96.doi: 10.3760/cma.j.issn.1673-422X.2014.02.005

Th22细胞及IL-22在肿瘤中的作用

刘国芳, 向晓星

225000 扬州大学临床医学院

收稿日期:2013-04-16 修回日期:2013-11-06 出版日期:2014-02-08 发布日期:2014-01-26
通讯作者: 向晓星，E-mail: yzxiangxx@sina.com E-mail:yzxiangxx@sina.com

Effects of Th22 cells and IL-22 in tumors

Liu Guofang, Xiang Xiaoxing

Clinical Medicine College of Yangzhou University, Yangzhou 225000, China

Received:2013-04-16 Revised:2013-11-06 Online:2014-02-08 Published:2014-01-26
Contact: Xiang Xiaoxing E-mail:yzxiangxx@sina.com

摘要/Abstract

摘要： Th22细胞是新发现的一类CD4+T辅助细胞亚群，以分泌白细胞介素（IL）22，而不分泌IL17和干扰素γ（IFNγ）为特点。已有研究显示，Th22细胞参与自身免疫性疾病、感染性疾病等的免疫过程。最近研究证实，Th22细胞及其细胞因子在多种肿瘤组织中分布和表达，但在肿瘤发生发展过程中是起抑制作用还是促进作用目前结论不一。关于Th22在肿瘤中的表达和作用机制的研究可以为肿瘤的特异性靶向治疗提供理论依据。

关键词: 肿瘤, Th22细胞, 白细胞介素22

Abstract: Th22 cells, a new subset of CD4+ Thelper cells, and is characterized by secreting interleukin (IL)22 but not IL17 or interferon (IFN)γ. Research shows that Th22 cells participate in the immunologic processes of autoimmune diseases and infectious diseases. Recent studies confirm that Th22 cells and related cytokines distribute and express in a verity of tumor tissues, but the conclusions of their repressive or stimulative functions in tumorigenesis are different. The studies on Th22 cell expression in tumors and its underlying mechanism can provide a theoretical basis for specific targeted tumor therapy.

Key words: Neoplasms, T helper 22, Interleukin-22

刘国芳, 向晓星. Th22细胞及IL-22在肿瘤中的作用[J]. 国际肿瘤学杂志, 2014, 41(2): 93-96.

Liu Guofang, Xiang Xiaoxing. Effects of Th22 cells and IL-22 in tumors[J]. Journal of International Oncology, 2014, 41(2): 93-96.

参考文献

［1］ Wolk K, Witte E, Witte K, et al. Biology of interleukin22［J］. Semin Immunopathol, 2010, 32(1): 17-31. ［2］ Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17cellmediated autoimmunity to environmental toxins［J］. Nature, 2008, 453(7191): 106-109. ［3］ Dardalhon V, Awasthi A, Kwon H, et al. IL4 inhibits TGFbetainduced Foxp3+ T cells and, together with TGFbeta, generates IL9+ IL10+ Foxp3() effector T cells［J］. Nat Immunol, 2008, 9(12):1347-1355. ［4］ Fujita H, Nograles KE, Kikuchi T, et al. Human Langerhans cells induce distinct IL22producing CD4+ T cells lacking IL17 production［J］. Proc Natl Acad Sci USA, 2009, 106(51):21795-21800. ［5］ Blumberg H, Conklin D, Xu WF, et al. Interleukin 20: discovery, receptor identification, and role in epidermal function［J］. Cell, 2001, 104(1):9-19. ［6］ Leipe J, Schramm MA, Grunke M, et al. Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis［J］. Ann Rheum Dis, 2011, 70(8):1453-1457. ［7］ Pickert G, Neufert C, Leppkes M, et al. STAT3 links IL22 signaling in intestinal epithelial cells to mucosal wound healing［J］. J Exp Med, 2009, 206(7):1465-1472. ［8］ Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)17, T(H)1 and T(H)2 cells［J］. Nat Immunol, 2009, 10(8):864-871. ［9］ Xie MH, Aggarwal S, Ho WH, et al. Interleukin (IL)22, a novel human cytokine that signals through the interferon receptorrelated proteins CRF24 and IL22R［J］. J Biol Chem, 2000, 275(40):31335-31339. ［10］ Jones BC, Logsdon NJ, Walter MR. Structure of IL22 bound to its highaffinity IL22R1 chain［J］. Structure, 2008, 16(9):1333-1344. ［11］ Eyerich S, Wagener J, Wenzel V, et al. IL22 and TNFα represent a key cytokine combination for epidermal integrity during infection with Candida albicans［J］. Eur J Immunol, 2011, 41(7):1894-1901. ［12］ Wolk K, Kunz S, Witte E, et al. IL22 increases the innate immunity of tissues［J］. Immunity, 2004, 21(2):241-254. ［13］ Tian T, Yu S, Ma D. Th22 and related cytokines in inflammatory and autoimmune diseases［J］. Expert Opin Ther Targets, 2013, 17(2):113125. ［14］ Fang JS, Gillies RD, Gatenby RA. Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression［J］. Semin Cancer Biol, 2008, 18(5):330-337. ［15］ Jiang R, Tan Z, Deng L, Chen Y, et al. Interleukin22 promotes human hepatocellular carcinoma by activation of STAT3［J］. Hepatology, 2011, 54(3):900-909. ［16］ Park O, Wang H, Weng H, et al. In vivo consequences of liverspecific interleukin22 expression in mice: implications for human liver disease progression［J］. Hepatology, 2011, 54(1):252-261. ［17］ Liu T, Peng L, Yu P, et al. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer［J］. J Clin Immunol, 2012, 32(6):1332-1339. ［18］ Zhuang Y, Peng LS, Zhao YL, et al. Increased intratumoral IL22producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival［J］. Cancer Immunol Immunother, 2012, 61(11):1965-1975. ［19］ Zhang W, Chen Y, Wei H, et al. Antiapoptotic activity of autocrine interleukin22 and therapeutic effects of interleukin22small interfering RNA on human lung cancer xenografts［J］. Clin Cancer Res, 2008, 14(20):6432-6439. ［20］ Ye ZJ, Zhou Q, Yin W, et al. Interleukin 22producing CD4+ T cells in malignant pleural effusion［J］. Cancer Lett, 2012, 326(1):23-32. ［21］ Liu LM, Zhang XX, Zhang YM. The change of peripheral blood Th22 cells in patients with acute myeloid leukemia［J］. Zhonghua Xue Ye Xue Za Zhi, 2012, 33(2):133-135. ［22］ Weber GF, Gaertner FC, Erl W, et al. IL22mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2M phase［J］. J Immunol, 2006, 177(11):8266-8272.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

Th22细胞及IL-22在肿瘤中的作用

Effects of Th22 cells and IL-22 in tumors

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价